Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
Year: 2013
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. METHOD: Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). RESULTS: In a group of 168 patients with MS who were undergoing treatment with natalizumab, JCV-DNA was detectable in 86 (51.2%) patients. DISCUSSION: Data on JCV-DNA in Brazil add to the worldwide assessment of the prevalence of the JCV in MS patients requiring treatment with natalizumab.
Source: Arquivos de Neuro-Psiquiatria
Authors: Yara Dadalti Fragoso, Maria Fernanda Mendes, Walter Oleschko Arruda, Jefferson Becker, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Elizabeth Regina Comini-Frota, Renan Barros Domingues, Maria Lucia Brito Ferreira, Alessandro Finkelsztejn, Paulo Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Goncalves, Damacio Ramon Kaimen-Maciel, Rogerio de Rizo Morales, Andre Muniz, Heloisa Helena Ruocco, Pedro Rippel Salgado, Livia Brito Bezerra de Albuquerque, Rodrigo Assad Diniz da Gama, Sergio Georgeto, Josiane Lopes, Celso Luis Silva Oliveira, Francisco Tomaz Meneses Oliveira, Juliana Safanelli, Patricia Correia de Oliveira Saldanha, Massaco Satomi
Institutions: Universidade Metropolitana de Santos, Universidade Federal do Paraná, Pontifícia Universidade Católica do Rio Grande do Sul, Fundação do ABC, Universidade Federal de Minas Gerais, Hospital da Restauração, Hospital de Clínicas de Porto Alegre, Pontifícia Universidade Católica de São Paulo, Universidade da Região de Joinville, Universidade Estadual de Londrina, Universidade Federal de Uberlândia, Hospital São Rafael, Universidade Federal de Mato Grosso do Sul
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $200
OpenAlex ID: W2019110331